RJ Hamster
📈 Investor’s Insight: Dive into the Stock Report for…
A New National Moment (Ad)
Read their full investigation and see which assets could benefit ▷
STOCK OF THE DAY
Disc Medicine (NASDAQ:IRON)
CURRENT PRICE
$60.09-1.92 (-3.10%)(As of 04:00 PM ET)30 DAY PERFORMANCE-10.17% 90 DAY PERFORMANCE-25.20% 1 YEAR PERFORMANCE +14.52%
MARKET CAPITALIZATION
$2.29B
PRICE TARGET
$104.80
NET INCOME
-$212.18M
ABOUT DISC MEDICINE
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. The company’s pipeline is anchored by lead programs… Read Full Profile ▷
IRON COMPANY CALENDAR
FEB 26, 2026Last EarningsMAR 27, 2026TodayMAY 6, 2026Next Earnings (Estimated)DEC 31, 2026Fiscal Year End
RECENT DISC MEDICINE NEWS
FRI. MARCH 27, 2026 9:00 AM EST | GLOBENEWSWIRE.COM
Disc Medicine, Inc. Investigated by the Portnoy Law FirmTHU. MARCH 26, 2026 4:30 PM EST | GLOBENEWSWIRE.COM
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoi…THU. MARCH 26, 2026 10:00 AM EST | PRNEWSWIRE.COM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc….THU. MARCH 26, 2026 3:04 AM EST | MARKETBEAT.COM
Assenagon Asset Management S.A. Grows Position in Disc Medicine, Inc. $IRONWED. MARCH 25, 2026 9:00 AM EST | PRNEWSWIRE.COM
IRON Investors Lose Up to $22/Share — LEVI & KORSINSKY, LLP Investigates Disc Medicine
Top Stock News for Friday, March 27th
Trump Did What!?!? (Ad)
Louis Navellier recently visited Mar-a-Lago and says he’s found what could be his biggest winner yet – a single stock tied to President Trump, Elon Musk, and a major shift in the AI revolution.
Navellier is putting his reputation on the line and urging investors to consider this one name above all others in 2026. The company sits at the center of a story involving trillions of dollars and a coming upgrade to artificial intelligence.See the name and ticker symbol of the company Navellier recommends ▷
Braze Stock Rallies as Revenue Beats, Buybacks Begin, and Outlook Jumps
Braze, Inc. is rebounding after a hot report affirms its growth outlook. AI disruptions are good for this business and driving profits.Read The Full Story ▷
Karman Tanks 14%: Opportunity or Warning for This Defense Darling
Following a standout 2025, defense newcomer Karman just took a huge post-earnings hit. Still, amid “generational” demand, KRMN remains confident in its future.Read The Full Story ▷
Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)
We’ve found The Next Elon Musk… and what we believe to be the next Tesla.
It’s already racked up $26 billion in government contracts.
Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free. ▷
Ondas Inc. Flywheel Gains Momentum, Vertical Liftoff Imminent
Ondas Inc. is gaining momentum, accelerating business, and is on track to profitability. Headwinds are easing, and stock price liftoff is imminent.Read The Full Story ▷
KB Home’s Earnings Slump Puts Dividends and Buybacks at Risk
KB Home is a high-quality stock experiencing a low-quality period, with capital returns at risk and lower stock prices likely.Read The Full Story ▷
Small-cap MedTech with multiple profitable quarters and $25.50 upside (Ad)
BioStem Technologies (BSEM) entered 2026 with a strategic acquisition of BioTissue Holdings’ surgical and wound care assets, expanding its total addressable market to an estimated 300-350 million dollars across trauma, burns, and soft-tissue repair.
Unlike most small-cap MedTech names, BSEM has delivered multiple profitable quarters, maintained high gross margins, and preserved cash post-acquisition. Zacks Small Cap Research has highlighted a price target of 25.50, with a potential Nasdaq uplisting adding to the institutional case.Dig deeper into why BSEM is one of the most compelling small-cap MedTech stories today ▷
Big Tech Just Got Hit—Why This Lawsuit Could Change Social Media Forever
Though the damages from the recent social media trial involving Meta and Google are in the millions, the potential implications are much larger.Read The Full Story ▷
MarketBeat Media, LLC dba StockReport.com
345 N Reid Place, Suite 620
Sioux Falls, SD 57103.
contact@stockreport.comUnsubscribe ▷
